Puma Biotechnology, Inc. (NYSE: PBYI) announced that results from the ExteNET Phase III clinical trial of neratinib in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE